Diversified’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$353K Buy
4,053
+1
+0% +$86 0.04% 161
2024
Q2
$333K Buy
4,052
+2
+0% +$159 0.04% 159
2024
Q1
$325K Buy
4,050
+1
+0% +$77 0.04% 120
2023
Q4
$308K Sell
4,049
-211
-5% -$15.1K 0.07% 111
2023
Q3
$308K Buy
4,260
+1
+0% +$77 0.08% 100
2023
Q2
$322K Buy
4,259
+2
+0% +$153 0.08% 100
2023
Q1
$324K Sell
4,257
-98
-2% -$7.55K 0.12% 98
2022
Q4
$342K Buy
4,355
+1
+0% +$77 0.13% 101
2022
Q3
$310K Buy
4,354
+51
+1% +$3.8K 0.16% 84
2022
Q2
$323K Sell
4,303
-132
-3% -$10K 0.13% 74
2022
Q1
$353K Buy
4,435
+1
+0% +$78 0.14% 80
2021
Q4
$360K Buy
4,434
+2
+0% +$158 0.15% 80
2021
Q3
$343K Buy
4,432
+9
+0.2% +$726 0.18% 75
2021
Q2
$356K Buy
4,423
+9
+0.2% +$715 0.2% 72
2021
Q1
$348K Buy
4,414
+15
+0.3% +$1.17K 0.27% 66
2020
Q4
$281K Buy
+4,399
New +$294K 0.24% 72

Other funds holding PJP

Diversified's PJP Position: Q3 2024 in Review

Diversified increased its Invesco Pharmaceuticals ETF (PJP) stake by 0.02% in Q3 2024, buying an estimated $86 and bringing the position to 4,053 shares worth $353K. The position accounts for 0.04% of the portfolio, ranked #161.

Diversified first reported a position in PJP in Q4 2020 and has held it in 16 quarters since. The position peaked at $360K in Q4 2021. 97 funds tracked by Wall St. Rank hold PJP as of Q3 2024.

  • Diversified held 4,053 shares of Invesco Pharmaceuticals ETF worth $353K as of Q3 2024.
  • Diversified bought 1 Invesco Pharmaceuticals ETF share in Q3 2024, an estimated $86.
  • Invesco Pharmaceuticals ETF made up 0.04% of Diversified's portfolio in Q3 2024, its #161 holding.
  • Diversified first reported a position in Invesco Pharmaceuticals ETF in Q4 2020 and has held it in 16 quarters since.
  • Diversified's Invesco Pharmaceuticals ETF position peaked at $360K in Q4 2021.
  • 97 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2024.

Based on Diversified's 13F filing for Q3 2024, filed 13 Nov 2024.